|
1
|
Robinson BW and Lake RA: Advances in
malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Delgermaa V, Takahashi K, Park EK, Le GV,
Hara T and Sorahan T: Global mesothelioma deaths reported to the
World Health Organization between 1994 and 2008. Bull World Health
Organ. 89:716–724. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alkhateeb AA and Connor JR: The
significance of ferritin in cancer: Anti-oxidation, inflammation
and tumorigenesis. Biochim Biophys Acta. 1836:245–254.
2013.PubMed/NCBI
|
|
4
|
Gomez DR, Rimner A, Simone CB II, Cho BCJ,
de Perrot M, Adjei AA, Bueno R, Gill RR, Harpole DH Jr, Hesdorffer
M, et al: The use of radiation therapy for the treatment of
malignant pleural mesothelioma: Expert opinion from the National
Cancer Institute thoracic malignancy steering committee,
International Association for the Study of Lung Cancer, and
Mesothelioma Applied Research Foundation. J Thorac Oncol.
14:1172–1183. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
de Gooijer CJ, Baas P and Burgers JA:
Current chemotherapy strategies in malignant pleural mesothelioma.
Transl Lung Cancer Res. 7:574–583. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aung W, Hasegawa S, Furukawa T and Saga T:
Potential role of ferritin heavy chain in oxidative stress and
apoptosis in human mesothelial and mesothelioma cells: Implications
for asbestos-induced oncogenesis. Carcinogenesis. 28:2047–2052.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Z, Liu J, Chen H, Zhang Y, Shi H, Huang
L, Tao J, Shen R and Wang T: Ferritin light chain (FTL) competes
with long noncoding RNA Linc00467 for miR-133b binding site to
regulate chemoresistance and metastasis of colorectal cancer.
Carcinogenesis. 41:467–477. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang L, Chen Z and Xu A: FTL: A novel
predictor in gastric cancer. Int J Clin Exp Pathol. 10:7865–7872.
2017.PubMed/NCBI
|
|
9
|
Wu T, Li Y, Liu B, Zhang S, Wu L, Zhu X
and Chen Q: Expression of ferritin light chain (FTL) is elevated in
glioblastoma, and FTL silencing inhibits glioblastoma cell
proliferation via the GADD45/JNK pathway. PLoS One.
11:e01493612016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang H, Qiu Y, Huang G, Zhou X, Zhou X
and Luo W: Value of Ferritin Heavy Chain (FTH1) Expression in
diagnosis and prognosis of renal cell carcinoma. Med Sci Monit.
19:3700–3715. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mohr S, Bottin MC, Lannes B, Neuville A,
Bellocq JP, Keith G and Rihn BH: Microdissection, mRNA
amplification and microarray: A study of pleural mesothelial and
malignant mesothelioma cells. Biochimie. 86:13–19. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The cancer cell line encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuraoka M, Amatya VJ, Kushitani K, Mawas
AS, Miyata Y, Okada M, Kishimoto T, Inai K, Nishisaka T, Sueda T
and Takeshima Y: Identification of DAB2 and Intelectin-1 as novel
positive immunohistochemical markers of epithelioid mesothelioma by
transcriptome microarray analysis for its differentiation from
pulmonary adenocarcinoma. Am J Surg Pathol. 41:1045–1052. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lamprecht MR, Sabatini DM and Carpenter
AE: CellProfiler: Free, versatile software for automated biological
image analysis. Biotechniques. 42:71–75. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao C, Tian D, Park J, Allan J, Pataky KA
and Yan TD: A systematic review and meta-analysis of surgical
treatments for malignant pleural mesothelioma. Lung Cancer.
83:240–245. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Flores RM, Riedel E, Donington JS, Alago
W, Ihekweazu U, Krug L, Rosenzweig K, Adusumilli PS, Carbone M and
Pass HI: Frequency of use and predictors of cancer-directed surgery
in the management of malignant pleural mesothelioma in a
community-based (Surveillance, Epidemiology, and End Results
[SEER]) population. J Thorac Oncol. 5:1649–1654. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baas P, Scherpereel A, Nowak AK, Fujimoto
N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, et
al: First-line nivolumab plus ipilimumab in unresectable malignant
pleural mesothelioma (CheckMate 743): A multicentre, randomised,
open-label, phase 3 trial. Lancet. 397:375–386. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Z, Jiang L, Chew SH, Hirayama T, Sekido
Y and Toyokuni S: Carbonic anhydrase 9 confers resistance to
ferroptosis/apoptosis in malignant mesothelioma under hypoxia.
Redox Biol. 26:1012972019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shi L, Ito F, Wang Y, Okazaki Y, Tanaka H,
Mizuno M, Hori M, Hirayama T, Nagasawa H, Richardson DR and
Toyokuni S: Non-thermal plasma induces a stress response in
mesothelioma cells resulting in increased endocytosis, lysosome
biogenesis and autophagy. Free Radic Biol Med. 108:904–917. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma T, Van Tine BA, Wei Y, Garrett MD,
Nelson D, Adams PD, Wang J, Qin J, Chow LT and Harper JW: Cell
cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in
Cajal bodies promotes histone gene transcription. Genes Dev.
14:2298–2313. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Okuda M, Horn HF, Tarapore P, Tokuyama Y,
Smulian AG, Chan PK, Knudsen ES, Hofmann IA, Snyder JD, Bove KE and
Fukasawa K: Nucleophosmin/B23 is a target of CDK2/cyclin E in
centrosome duplication. Cell. 103:127–140. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sever-Chroneos Z, Angus SP, Fribourg AF,
Wan H, Todorov I, Knudsen KE and Knudsen ES: Retinoblastoma tumor
suppressor protein signals through inhibition of cyclin-dependent
kinase 2 activity to disrupt PCNA function in S phase. Mol Cell
Biol. 21:4032–4045. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Herrera RE, Sah VP, Williams BO, Mäkelä
TP, Weinberg RA and Jacks T: Altered cell cycle kinetics, gene
expression, and G1 restriction point regulation in Rb-deficient
fibroblasts. Mol Cell Biol. 16:2402–2407. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu W, Giangrande PH and Nevins JR: E2Fs
link the control of G1/S and G2/M transcription. EMBO J.
23:4615–4626. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Markey MP, Angus SP, Strobeck MW, Williams
SL, Gunawardena RW, Aronow BJ and Knudsen ES: Unbiased analysis of
RB-mediated transcriptional repression identifies novel targets and
distinctions from E2F action. Cancer Res. 62:6587–6597.
2002.PubMed/NCBI
|
|
26
|
Möröy T and Geisen C: Cyclin E. Int J
Biochem Cell Biol. 36:1424–1439. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ren B, Cam H, Takahashi Y, Volkert T,
Terragni J, Young RA and Dynlacht BD: E2F integrates cell cycle
progression with DNA repair, replication, and G(2)/M checkpoints.
Genes Dev. 16:245–256. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Scaltriti M, Eichhorn PJ, Cortés J,
Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A,
Ibrahim YH, et al: Cyclin E amplification/overexpression is a
mechanism of trastuzumab resistance in HER2+ breast cancer
patients. Proc Natl Acad Sci USA. 108:3761–3766. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Polyak K, Lee MH, Erdjument-Bromage H,
Koff A, Roberts JM, Tempst P and Massagué J: Cloning of p27Kip1, a
cyclin-dependent kinase inhibitor and a potential mediator of
extracellular antimitogenic signals. Cell. 78:59–66. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van den Heuvel S and Harlow E: Distinct
roles for cyclin-dependent kinases in cell cycle control. Science.
262:2050–2054. 1993. View Article : Google Scholar : PubMed/NCBI
|
